Katie Jenkins
Family · Austin, INNPI 1740053677
Payments from drug & device makers
Across 148 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$644
- AbbVie$606
- Gilead$233
- Alkermes, Inc.$141
- GSK$93
- Exact Sciences$79
- plus $652 from 17 others
What the payments were for
- Food & beverage$2,447100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 32 | $644 |
| AbbVie | 47 | $606 |
| Gilead | 14 | $233 |
| Alkermes, Inc. | 7 | $141 |
| GSK | 6 | $93 |
| Exact Sciences | 3 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Indivior Inc. | 5 | $74 |
| Merck | 3 | $64 |
| Bayer | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Lundbeck LLC | 3 | $49 |
| EMD Serono, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Pfizer | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Corium, LLC | 1 | $14 |
How this compares
$2,447 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $11,369 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 92 | $2,934 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $305 |
| Methocarbamol | 12 | $276 |
| Gabapentin | 22 | $226 |
| Omeprazole | 13 | $119 |
| Ibuprofen | 14 | $89 |
| Ropinirole Hcl | 12 | $70 |
| Prednisone | 14 | $31 |
| Losartan Potassium | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $35 | $11,36911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Austin
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.